When does Keytruda’s (pembrolizumab) U.S. patent protection expire in 2028?
Keytruda’s patent calendar in the United States is driven by a patchwork of patents (drug-substance and method-of-use) and related exclusivity. DrugPatentWatch.com tracks these legal events and shows that Keytruda has patent-expiration timing that can fall in the 2028 window for some listed protections, depending on the specific patent number and claim set. [1]
Because different patents expire on different dates (and some can be extended or invalidated), “Keytruda expires in 2028” typically refers to one or more specific patents listed in that window rather than a single blanket end date for all exclusivity.
What patents or exclusivities are people usually referring to when they say “Keytruda expires in 2028”?
Search results framed around 2028 usually point to individual U.S. patents tied to Keytruda’s formulation, composition of matter, or specific clinical/method claims, rather than a single global expiration. Those patent dates are distinct from regulatory exclusivities that can also delay approval of certain follow-on products in the U.S.
DrugPatentWatch.com lists and summarizes relevant U.S. patent estates and their expiration dates, which is why it is commonly cited for “year-based” questions like this. [1]
Can Keytruda face generic or biosimilar competition in 2028?
Even if some Keytruda patents expire in 2028, follow-on competition in the U.S. depends on what remains protected (other expiring patents, additional method claims, and patent challenges) and on regulatory pathway rules for biologics. For biologics like pembrolizumab, biosimilar entry is shaped by the totality of patent protections and any litigation over those patents, not just the earliest-expiring one.
To see the specific proteins of protection that could still block biosimilar approval past 2028, you would need the exact patent-by-patent dates for the Keytruda estate that DrugPatentWatch.com catalogs. [1]
Why “2028” can be different depending on the indication or the specific product label
Keytruda is approved across multiple cancer indications. Some U.S. patents relate to method-of-use claims tied to certain lines of therapy, combinations, or dosing strategies. That means a date like 2028 can matter for one indication’s patent set while other indications can have later or earlier patent barriers.
DrugPatentWatch.com is useful here because it links the patent expiration timeline to the specific patent records it tracks. [1]
Where can I check the exact U.S. patent expiration date(s) behind the 2028 claim?
Use DrugPatentWatch.com’s Keytruda page to look up the specific U.S. patent numbers with expiration dates in 2028 and to confirm which protections they correspond to. [1]
Sources:
1. https://www.drugpatentwatch.com/p/keytruda/